bullish

Jacobio Pharma: More Thinking on Valuation

345 Views21 Nov 2020 00:08
Our DCF analysis of Jacobio Pharma results in a US$1.1B pre-money valuation based on the company's lead compounds and the AbbVie license agreement. We also include questions for management.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x